Skip to Content

Idarubicin

In the US, Idarubicin (idarubicin systemic) is a member of the drug class antibiotics/antineoplastics and is used to treat Acute Myeloid Leukemia, Leukemia, Leukocytoclastic Vasculitis and Solid Tumors.

US matches:

UK matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01DB06

CAS registry number (Chemical Abstracts Service)

0058957-92-9

Chemical Formula

C26-H27-N-O9

Molecular Weight

497

Therapeutic Category

Antineoplastic agent: Cytotoxic antibacterial from the group of anthracyclines

Chemical Name

(7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexapyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphtacenedione

Foreign Names

Generic Names

Brand Names

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide